-
1
-
-
0034715977
-
Crohn's disease associated with spondylarthropathy: effect of TNFα blockade with infliximab on articular symptoms
-
Van den Bosch F., Kruithof E., De Vos M., et al. Crohn's disease associated with spondylarthropathy: effect of TNFα blockade with infliximab on articular symptoms. Lancet 356 (2000) 1821-1822
-
(2000)
Lancet
, vol.356
, pp. 1821-1822
-
-
Van den Bosch, F.1
Kruithof, E.2
De Vos, M.3
-
2
-
-
0028903218
-
Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis
-
Braun J., Bollow M., Neure L., et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38 (1995) 499-505
-
(1995)
Arthritis Rheum
, vol.38
, pp. 499-505
-
-
Braun, J.1
Bollow, M.2
Neure, L.3
-
3
-
-
0021272107
-
Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New-York criteria
-
Van der Linden S., Valkenburg H.A., and Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New-York criteria. Arthritis Rheum 27 (1984) 361-368
-
(1984)
Arthritis Rheum
, vol.27
, pp. 361-368
-
-
Van der Linden, S.1
Valkenburg, H.A.2
Cats, A.3
-
4
-
-
0036852331
-
Efficacy of infliximab in refractory ankylosing spondylitis: results of a six month open-label study
-
Breban M., Vignon E., Claudepierre P., et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six month open-label study. Rheumatology (Oxford) 41 (2002) 1280-1285
-
(2002)
Rheumatology (Oxford)
, vol.41
, pp. 1280-1285
-
-
Breban, M.1
Vignon, E.2
Claudepierre, P.3
-
5
-
-
0036188187
-
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy
-
Van den Bosch F., Kruithof E., Baeten D., et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 46 (2002) 755-765
-
(2002)
Arthritis Rheum
, vol.46
, pp. 755-765
-
-
Van den Bosch, F.1
Kruithof, E.2
Baeten, D.3
-
6
-
-
0345490895
-
Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study
-
Temekonidis T.I., Alamanos Y., Nikas S., et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 62 (2003) 1218-1220
-
(2003)
Ann Rheum Dis
, vol.62
, pp. 1218-1220
-
-
Temekonidis, T.I.1
Alamanos, Y.2
Nikas, S.3
-
7
-
-
0034094123
-
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab
-
Brandt J., Haibel H., Cornely D., et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43 (2000) 1346-1352
-
(2000)
Arthritis Rheum
, vol.43
, pp. 1346-1352
-
-
Brandt, J.1
Haibel, H.2
Cornely, D.3
-
8
-
-
0037029430
-
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial
-
Braun J., Brandt J., Listing J., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359 (2002) 1187-1193
-
(2002)
Lancet
, vol.359
, pp. 1187-1193
-
-
Braun, J.1
Brandt, J.2
Listing, J.3
-
9
-
-
0042072982
-
Long term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial
-
Braun J., Brandt J., Listing J., et al. Long term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 48 (2003) 2224-2233
-
(2003)
Arthritis Rheum
, vol.48
, pp. 2224-2233
-
-
Braun, J.1
Brandt, J.2
Listing, J.3
-
10
-
-
0038423033
-
for the ASAS Working Group. International ASAS consensus statement for the use of anti-tumor necrosis factor agents in patients with ankylosing spondylitis
-
Braun J., Pham T., Sieper J., et al. for the ASAS Working Group. International ASAS consensus statement for the use of anti-tumor necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62 (2003) 817-824
-
(2003)
Ann Rheum Dis
, vol.62
, pp. 817-824
-
-
Braun, J.1
Pham, T.2
Sieper, J.3
-
11
-
-
0028575453
-
A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index
-
Garrett S., Jenkinson T., Kennedy L.G., et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21 (1994) 2286-2291
-
(1994)
J Rheumatol
, vol.21
, pp. 2286-2291
-
-
Garrett, S.1
Jenkinson, T.2
Kennedy, L.G.3
-
12
-
-
0034130272
-
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study
-
Van den Bosch F., Kruithof E., Baeten D., et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 59 (2000) 428-433
-
(2000)
Ann Rheum Dis
, vol.59
, pp. 428-433
-
-
Van den Bosch, F.1
Kruithof, E.2
Baeten, D.3
-
14
-
-
0026003027
-
The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy
-
Dougados M., Van den Linden S., Juhlin R., et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34 (1991) 1218-1227
-
(1991)
Arthritis Rheum
, vol.34
, pp. 1218-1227
-
-
Dougados, M.1
Van den Linden, S.2
Juhlin, R.3
-
15
-
-
0028579768
-
A new approach to defining functional ability in ankylosing spondylitis: the Bath Ankylosing Spondylitis Functional Index
-
Calin A., Garrett S., Whitelock H., et al. A new approach to defining functional ability in ankylosing spondylitis: the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21 (1994) 2281-2285
-
(1994)
J Rheumatol
, vol.21
, pp. 2281-2285
-
-
Calin, A.1
Garrett, S.2
Whitelock, H.3
-
16
-
-
0042508748
-
for the ASAS Working Group: initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group
-
Pham T., Van der Heijde D., Calin A., et al. for the ASAS Working Group: initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group. Ann Rheum Dis 62 (2003) 812-816
-
(2003)
Ann Rheum Dis
, vol.62
, pp. 812-816
-
-
Pham, T.1
Van der Heijde, D.2
Calin, A.3
-
17
-
-
33144469246
-
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
-
Braun J., Davis J., Dougados M., et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65 (2006) 316-320
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 316-320
-
-
Braun, J.1
Davis, J.2
Dougados, M.3
-
18
-
-
19544388586
-
Infliximab treatment in ankylosing spondylitis: an observational study
-
Nikas S.N., Alamanos Y., Voulgari P.V., et al. Infliximab treatment in ankylosing spondylitis: an observational study. Ann Rheum Dis 64 (2005) 940-942
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 940-942
-
-
Nikas, S.N.1
Alamanos, Y.2
Voulgari, P.V.3
-
19
-
-
36849016433
-
Club Rhumatismes et Inflammation (CRI/SFR). Recommendations of the French Society of Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update
-
Pham T., Fautrel B., Dernis E., et al. Club Rhumatismes et Inflammation (CRI/SFR). Recommendations of the French Society of Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 74 (2007) 638-646
-
(2007)
Joint Bone Spine
, vol.74
, pp. 638-646
-
-
Pham, T.1
Fautrel, B.2
Dernis, E.3
-
20
-
-
34248137517
-
Efficacy of adalimumab in the treatment of preradiographic axial spondyloarthritis: results of a 12-week, randomized controlled trial
-
[abstract]
-
Haibel H., Rudwaleit M., Heldmann F., et al. Efficacy of adalimumab in the treatment of preradiographic axial spondyloarthritis: results of a 12-week, randomized controlled trial. [abstract]. Arthritis Rheum 54 Suppl (2006) L24
-
(2006)
Arthritis Rheum
, vol.54
, Issue.SUPPL
-
-
Haibel, H.1
Rudwaleit, M.2
Heldmann, F.3
-
21
-
-
58149194663
-
Efficacy of adalimumab in the treatment of preradiographic axial spondyloarthritis: 52-week results of a randomized controlled trial and open-label extension
-
(abstract 753)
-
Haibel H., Rudwaleit M., Amtenbrink A., et al. Efficacy of adalimumab in the treatment of preradiographic axial spondyloarthritis: 52-week results of a randomized controlled trial and open-label extension. Arthritis Rheum 56 9 Suppl. (2007) S320-S321 (abstract 753)
-
(2007)
Arthritis Rheum
, vol.56
, Issue.9 SUPPL
-
-
Haibel, H.1
Rudwaleit, M.2
Amtenbrink, A.3
-
22
-
-
58149189908
-
A randomized controlled trial of infliximab shows clinical and MRI efficacy in patients with HLA B27 positive very early ankylosing spondylitis
-
Barkham N., Keen H., Coates L., et al. A randomized controlled trial of infliximab shows clinical and MRI efficacy in patients with HLA B27 positive very early ankylosing spondylitis. Arthritis Rheum 56 Suppl (2006) L11
-
(2006)
Arthritis Rheum
, vol.56
, Issue.SUPPL
-
-
Barkham, N.1
Keen, H.2
Coates, L.3
|